Creative Biolabs has announced a focus on its tumor organoid and immune cell co-culture research services, including models designed to investigate CAR-T cell activity within three-dimensional tumor environments. The move addresses a persistent challenge in preclinical immuno-oncology: conventional two-dimensional cultures often fail to capture key aspects of tumor architecture and cellular interactions that influence immune responses.
Developing effective cancer immunotherapies requires models that reflect relevant tumor biology alongside immune cell behavior. While 2D cultures remain practical, they are limited in representing the spatial and structural complexity of real tumors. Tumor organoids provide an alternative by retaining selected characteristics of the original tumor in a 3D setting, enabling more physiologically relevant studies of treatment response. Creative Biolabs supports this through its tumor organoid modeling services for immuno-oncology research, which include monoculture and co-culture options, as well as patient-derived models for investigating individual differences in tumor behavior and drug response.
Adding immune cells expands the scope of questions these models can address. The company's tumor organoid and immune cell co-culture models are designed to help researchers examine interactions between tumor cells and various immune populations, including CAR-T cells, CAR-NK cells, tumor-infiltrating lymphocytes, and peripheral blood mononuclear cells. Such systems support studies of immune cell activity, tumor cell killing, and infiltration, with the choice of tumor samples, immune cell sources, and assays tailored to the research question.
Within this portfolio, the tumor organoid and CAR-T co-culture model specifically focuses on interactions between engineered T cells and tumor targets. The service covers organoid culture, CAR-T cell preparation, and co-culture construction, with applications in candidate screening and mechanistic research. Potential endpoints include tumor cell survival, CAR-T cell killing activity, proliferation, and cytokine release, which can help characterize candidate behavior and explore factors behind variable responses. Patient-derived organoid configurations further allow examination of sample-specific responses.
However, the company notes that organoid co-cultures do not fully reproduce the vascular, stromal, and systemic immune components of an in vivo tumor microenvironment. Results should therefore be interpreted as preclinical research findings rather than direct predictions of clinical response. By integrating tumor organoid construction with immune cell co-culture and functional assays, Creative Biolabs offers a coordinated approach for researchers studying immunotherapy responses, potentially accelerating the translation of promising CAR-T therapies from bench to bedside.
